Journal
INDIAN JOURNAL OF CANCER
Volume 52, Issue 4, Pages 568-+Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/0019-509X.178403
Keywords
Glioblastoma; mismatch repair; molecular; recurrent gliomas; O-6-Methylguanine-DNA methyltransferase
Categories
Ask authors/readers for more resources
Despite multimodality treatment protocol including surgical resection, radiotherapy, and chemotherapy in patients with glioblastoma multiforme (GBM), most suffer from treatment failure and tumor recurrence within a few months of initial surgery. The effectiveness of temozolomide (TMZ), the most commonly used chemotherapeutic agent, is largely dependent on the methylation status of the promoter of the gene O-6-methylguanine-DNA methyltransferase (MGMT) and the integrity of the mismatch repair (MMR) system. Changes in these regulatory mechanisms at the time of recurrence may influence response to therapy. Deciphering the molecular mechanisms of resistance to these drugs may in future lead to improvised patient management. In this article, we provide an update of the spectrum of molecular changes that occur in recurrent GBMs, and thus may have an impact on patient survival and treatment response. For review, electronic search for the keywords Recurrent GBM, Recurrent GBM AND MGMT Recurrent glioma AND MGMT, Recurrent GBM AND MMR and Recurrent glioma AND MMR, Recurrent GBM AND MMR and Recurrent glioma AND MMR was done on PubMed and relevant citations were screened including cross-references.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available